Telix Pharmaceuticals 관리

관리 기준 확인 3/4

Telix Pharmaceuticals CEO는 Chris Behrenbruch, Jul2023 에 임명되었습니다 의 임기는 1.83 년입니다. 총 연간 보상은 A$ 1.41M, 43.2% 로 구성됩니다. 43.2% 급여 및 56.8% 보너스(회사 주식 및 옵션 포함). 는 A$ 552.82M 가치에 해당하는 회사 주식의 6.4% 직접 소유합니다. 552.82M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 7.7 년입니다.

주요 정보

Chris Behrenbruch

최고 경영자

AU$1.4m

총 보상

CEO 급여 비율	43.17%
CEO 임기	1.8yrs
CEO 소유권	6.4%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	7.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chris Behrenbruch 의 보수는 Telix Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2024	AU$1m	AU$607k	AU$50m
Sep 30 2024	n/a	n/a	AU$50m
Jun 30 2024	n/a	n/a	AU$49m
Mar 31 2024	n/a	n/a	AU$32m
Dec 31 2023	AU$1m	AU$499k	AU$5m
Sep 30 2023	n/a	n/a	-AU$21m
Jun 30 2023	n/a	n/a	-AU$48m
Mar 31 2023	n/a	n/a	-AU$77m
Dec 31 2022	AU$865k	AU$422k	-AU$104m
Sep 30 2022	n/a	n/a	-AU$111m
Jun 30 2022	n/a	n/a	-AU$119m
Mar 31 2022	n/a	n/a	-AU$100m
Dec 31 2021	AU$620k	AU$374k	-AU$81m
Sep 30 2021	n/a	n/a	-AU$70m
Jun 30 2021	n/a	n/a	-AU$59m
Mar 31 2021	n/a	n/a	-AU$52m
Dec 31 2020	AU$421k	AU$295k	-AU$45m
Sep 30 2020	n/a	n/a	-AU$40m
Jun 30 2020	n/a	n/a	-AU$36m
Mar 31 2020	n/a	n/a	-AU$32m
Dec 31 2019	AU$460k	AU$317k	-AU$28m
Sep 30 2019	n/a	n/a	-AU$23m
Jun 30 2019	n/a	n/a	-AU$19m
Mar 31 2019	n/a	n/a	-AU$16m
Dec 31 2018	AU$380k	AU$280k	-AU$14m

보상 대 시장: Chris 의 총 보상 ($USD 903.93K ) Australian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 2.52M ).

보상과 수익: Chris 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Chris Behrenbruch (48 yo)

1.8yrs

테뉴어

AU$1,405,518

보상

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christian Behrenbruch	Co-Founder	1.8yrs	AU$1.41m	6.4% A$ 552.8m
Darren Smith	Group Chief Financial Officer	2.8yrs	AU$1.22m	0.0019% A$ 165.9k
Darren Patti	Group Chief Operating Officer	1.2yrs	AU$1.04m	0% A$ 0
Andreas Kluge	Chief Medical Advisor	no data	AU$104.92k	6.71% A$ 579.6m
David Cade	Group Chief Medical Officer	1.3yrs	AU$1.07m	0.11% A$ 9.5m
Richard Valeix	Chief Executive Officer of Telix Therapeutics	4yrs	AU$1.01m	0.037% A$ 3.2m
Paul Schaffer	Chief Technology Officer	less than a year	데이터 없음	데이터 없음
Michael Wheatcroft	Chief Scientist	4yrs	AU$167.76k	데이터 없음
Craig Ulrick	Chief Information Officer	2.3yrs	데이터 없음	데이터 없음
Kyahn Williamson	Senior Vice President of Corporate Communications & Investor Relations	3.8yrs	데이터 없음	데이터 없음
Lena Moran-Adams	Group General Counsel	2.7yrs	데이터 없음	데이터 없음
Thomas Fromm	Vice President of Sales	no data	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: TLX 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christian Behrenbruch	Co-Founder	8.3yrs	AU$1.41m	6.4% A$ 552.8m
Harry McCann	Independent Non-Executive Chairman	7.7yrs	AU$250.00k	0.33% A$ 28.6m
Chaitanya Divgi	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Rodney Hicks	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Neil Bander	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mark Nelson	Independent Non-Executive Director	7.7yrs	AU$103.30k	1.07% A$ 92.8m
Jann Skinner	Independent Non-Executive Director	6.9yrs	AU$111.56k	0.18% A$ 15.2m
Jean-François Chatal	Member of the Scientific Advisory Board	no data	데이터 없음	0% A$ 0
Jason Lewis	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Klaus Kopka	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Samuel Samnick	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marie McDonald	Independent Non-Executive Director	less than a year	데이터 없음	0.0011% A$ 95.0k

7.7yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: TLX 의 이사회는 경험(평균 재직 기간 7.7 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/15 11:07
장 마감 주가	2025/05/15 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Telix Pharmaceuticals Limited 16 애널리스트 중 10 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Russell Wright	Barclay Pearce Capital Pty Limited
John Hester	Bell Potter
Andrew Paine	CLSA

Telix Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Telix Pharmaceuticals Limited Appoints Paul Schaffer as Chief Technology Officer, Effective April 6, 2025

Telix Pharmaceuticals Limited Announces Appointment of Anne Whitaker as A Non-Executive Director Based in the United States, Effective 7 April 2025

Independent Non-Executive Chairman recently sold AU$913k worth of stock

Telix Pharmaceuticals Limited, Annual General Meeting, May 21, 2025

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Recent updates

Telix Pharmaceuticals Limited's Illuccix PSMA-PET Imaging Agent Approved in the Czech Republic

Telix Pharmaceuticals Limited Announces Illuccix Prostate Cancer PSMA-PET Imaging Agent Approve in Finland

Consensus EPS estimates increase by 14%

Telix Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2025

Telix Pharmaceuticals Limited Announces Preliminary Results from the Phase 2 IPAX-Linz Study of Tlx101

Telix Pharmaceuticals Limited Announces Preliminary Results from the Phase 2 IPAX-Linz Study of TLX101

Telix Pharmaceuticals Limited Prostate Cancer PSMA-PET Imaging Agent Approves in Sweden

Telix Pharmaceuticals Limited Appoints Paul Schaffer as Chief Technology Officer, Effective April 6, 2025

Telix Pharmaceuticals Limited Announces Appointment of Anne Whitaker as A Non-Executive Director Based in the United States, Effective 7 April 2025

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix

Now 24% undervalued

Telix Pharmaceuticals Limited Announces That the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria) Approves Illuccix®? (68Ga) Prostate Cancer Imaging Agent

Independent Non-Executive Chairman recently sold AU$913k worth of stock

Consensus EPS estimates increase by 39%

Telix Pharmaceuticals Limited Announces FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging

Telix Pharmaceuticals Limited Announces That the Biogenix Molecular Research Center Is Recruiting and Dosing Patients in the ProstACT Global Phase 3 Trial of TLX591 for Patients with Advanced Prostate Cancer

Telix Pharmaceuticals Limited's Illuccix PSMA-PET Imaging Agent Approved in Norway

Price target increased by 15% to AU$29.73

Full year 2024 earnings: EPS misses analyst expectations

Telix Pharmaceuticals Limited, Annual General Meeting, May 21, 2025

Telix Pharmaceuticals Limited Announces the United Kingdom Medicines and Healthcare Products Regulatory Agency Approves the Marketing Authorization Application for Its Prostate Cancer PET Imaging Agent Illuccix®

Telix Pharmaceuticals Limited Announces Danish Medicines Agency Approves its Prostate Cancer PET Imaging Agent Illuccix® (Kit for the Preparation of Gallium-68 Gozetotide Injection)

Consensus EPS estimates fall by 12%

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of Next-Generation Therapeutic Assets of ImaginAb, Inc.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of RLS (USA) Inc. from Rls Group Ltd.

Telix Pharmaceuticals Limited Receives Positive Decision on the Marketing Authorization Application for Its Prostate Cancer PET Imaging Agent Illuccix

Telix Pharmaceuticals Limited to Report Q4, 2024 Results on Feb 20, 2025

Telix Pharmaceuticals Limited Submits its Biologics License Application to the United States Food and Drug Administration for TLX250-CDx (Zircaix, Zr- girentuximab) Kidney Cancer Imaging

Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium

Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Consensus EPS estimates fall by 23%

Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent

Second quarter 2024 earnings: EPS misses analyst expectations

Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Price target increased by 12% to AU$24.04

Price target increased by 10% to AU$20.87

Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024

Price target increased by 14% to AU$21.49

Consensus EPS estimates increase by 10%

Price target increased by 11% to AU$18.89

Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million.

First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023)

Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent

Consensus EPS estimates increase by 10%

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Consensus EPS estimates increase by 30%

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Now 20% overvalued after recent price rise

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Consensus EPS estimates fall by 19%

Price target increased by 7.5% to AU$14.47

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022)

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Co-Founder exercised options to buy AU$1.7m worth of stock.

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent